Latest data from the Hong Kong Stock Exchange shows that on November 14, GL Capital Management GP Limited acquired an additional 4.4 million shares of ZYLOXTB (02190) at an average price of HK$24 per share, totaling HK$105.6 million. Following this purchase, GL Capital's total holdings in the company reached 20.5 million shares, representing a 6.09% stake.

Public records indicate that ZYLOXTB's current shareholders include prominent healthcare-focused investment firms such as Orbimed, Lake Bleu Capital, and AIHC Capital. The recent stake increase by GL Capital underscores market confidence in ZYLOXTB's operational stability and growth potential.

In recent years, ZYLOXTB has actively expanded its innovative product pipeline, accelerated the global rollout of its core products, and strengthened its international operations. The company stated that it remains committed to its mission of "Innovating for Life" by increasing R&D investments in medical technology to deliver high-quality, affordable medical device solutions to patients worldwide.